These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31230012)

  • 21. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.
    Chandra S; Arpa C; Menon D; Khalid H; Hamilton R; Nicholson L; Pal B; Fasolo S; Hykin P; Keane PA; Sivaprasad S
    Eye (Lond); 2020 Oct; 34(10):1888-1896. PubMed ID: 31980748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
    Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors affecting prognosis and need for anti-vascular endothelial growth factor injections in wet age-related macular degeneration.
    Kızılay ME; Şengün GD; Esen F; Durmuş E; Oğuz H; Aykut V
    Int Ophthalmol; 2024 Jul; 44(1):312. PubMed ID: 38963653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
    Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
    Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The fate of eyes with wet AMD beyond four years of anti-VEGF therapy.
    Garweg JG; Zirpel JJ; Gerhardt C; Pfister IB
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):823-831. PubMed ID: 29397436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning.
    Fu DJ; Faes L; Wagner SK; Moraes G; Chopra R; Patel PJ; Balaskas K; Keenan TDL; Bachmann LM; Keane PA
    Ophthalmol Retina; 2021 Nov; 5(11):1074-1084. PubMed ID: 33516917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
    Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
    Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
    Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting.
    Kataja M; Hujanen P; Huhtala H; Kaarniranta K; Tuulonen A; Uusitalo-Jarvinen H
    Br J Ophthalmol; 2018 Jul; 102(7):959-965. PubMed ID: 29074495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
    Khurana RN; Rahimy E; Joseph WA; Saroj N; Gibson A; Vitti R; Berliner AJ; Chu K; Cheng Y; Boyer DS
    Am J Ophthalmol; 2019 Apr; 200():161-168. PubMed ID: 30664844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
    Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
    Augsburger M; Sarra GM; Imesch P
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.